You are here

  • Home
  • Archive
  • Volume 81, Issue 6
  • Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study

Article info

Article menu
Download PDFPDF
Rheumatoid arthritis
Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study

Authors

  1. Correspondence to Dr Rishi J Desai, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts, USA; RDESAI{at}BWH.HARVARD.EDU
View Full Text

Citation

Khosrow-Khavar F, Kim SC, Lee H, et al
Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study
Annals of the Rheumatic Diseases 2022;81:798-804.

Publication history

  • Received November 24, 2021
  • Accepted December 30, 2021
  • First published January 13, 2022.
Online issue publication 
October 18, 2023

Article Versions

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.